Abivertinib
- Generic Name
- Abivertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26FN7O2
- CAS Number
- 1557267-42-1
- Unique Ingredient Identifier
- CER0OPG92L
- Background
Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodula...
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05361915
- Locations
- ๐บ๐ธ
Cleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธUCSD Moores Cancer Center, La Jolla, California, United States
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04440007
- Locations
- ๐บ๐ธ
MedStar Washington Hospital Center, Washington, District of Columbia, United States
๐บ๐ธTeradan Clinical Trials, Brandon, Florida, United States
๐บ๐ธQuality Clinical Research, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.